Tissue engineering uses various approaches to restore bone loss and heal critical-size defects resulting from trauma, infection, tumor resection or other musculoskeletal diseases. The success of bone tissue engineering strategies critically depends on the extent of blood vessel infiltration into the scaffolds. It has been demonstrated that blood vessel invasion from the host tissue into scaffolds is limited to a depth of several hundred micrometers. Limited vessel perfusion restricts the formation of bone in central regions of the scaffold, leads to loss of cell viability in this region and ultimately does not support healing of the defect. This review addresses the importance of vascularization in bone tissue engineering, discusses the key factors regulating the process of angiogenesis, and provides an overview of current approaches to direct blood vessel formation in biomaterials.
significant attention to fabricate scaffolds for musculoskeletal repair [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] . This is due to the capability of these polymers to fabricate scaffolds with high degree of biocompatibility, osteoconductivity and tunable mechanical properties. As an example, the osteoconductivity of PLGA scaffolds have been manifested by high levels of a bone marker, alkaline phosphatase (ALP) activity, by seeded osteoblasts [32] . The degradation of PLGA results in lactic and glycolic acids, both found naturally in the body [33] . To this end, a number of fabrication methods have been developed to synthesize PLGA into scaffolds with appropriate structure and mechanics. To name a few, we can refer to solvent casting particulate leaching, microsphere sintering, phase inversion, and prototyping techniques [19, 34] .
Growth factors can be incorporated into scaffolds to direct cell proliferation, migration, and differentiation. A significant number of studies have focused on selectively incorporating osteoinductive growth factors in the scaffolds [35] [36] [37] [38] . From the group of candidate factors, bone morphogenetic proteins (BMPs) have received significant attention in bone tissue engineering applications. BMP's 2 through 7 have been shown to elicit the healing of bone defects in a variety of in vivo models [39] [40] [41] [42] [43] [44] [45] [46] . Cells seeded on scaffolds may participate in neotissue formation and release growth factors that signal host cells to migrate into the scaffolds and differentiate into specific lineages. The tissue engineering community has used various sources of cells (e.g., osteoblasts) to recreate the building blocks of natural bone [47] [48] [49] [50] . For example, stem cells are uniquely positioned as the most promising cell source for tissue engineering strategies due to their capability of selfrenewal as well as the ability to differentiate into diverse cell types [51] [52] [53] [54] [55] [56] [57] . Control over stem cell self-renewal, differentiation and maintenance of stable cell lineage commitment is crucial for harnessing the cell plasticity and realizing its utility in regenerative medicine. The widespread research and clinical use of stem cell-derived tissues can be promoted by improved understanding of the cellular and molecular mechanisms of stem cell differentiation.
BONE IS A VASCULARIZED TISSUE
Like most other tissues, bone is highly vascularized and relies on blood vessels to supply nutrients such as oxygen and to facilitate removal of metabolic waste products. In the native bone tissues, constituent cells are present in a 100-200 m proximity to blood vessels and capillaries to ensure adequate transport of oxygen, nutrients and waste products [58, 59] . The critical role of vascularization in bone development, growth and repair has been well established [60] [61] [62] [63] [64] [65] [66] [67] [68] and is hypothesized to be the initiating factor in new bone formation [69] . While this claim is yet to be verified, there is substantial evidence that angiogenesis (formation of new blood vessels from pre-existing ones) is a critical process during endochondral ossification [70, 71] . In addition, the disruption of angiogenesis has been shown to inhibit the repair of femoral fractures and cortical bone defects in animal models [72] [73] [74] .
In bone tissue engineering applications using porous materials, it is desirable that scaffolds allow for early internal development of functional blood vessels. Neovascularization within the scaffolds reduces the impediment to biochemical transport relative to diffusion through the otherwise present fibrous capsule characteristics of the classical foreign body response (FBR) [75, 76] . Mitigating the FBR in this way allows for optimal nutrient/waste transport for engineered tissues that are grown in porous scaffolds and has the potential to promote rapid, controllable dosing in drug delivery and immuno-isolated gene and cell based implant therapies [77] .
To fully realize the promise of bone tissue engineering therapies, it is vital that we explore strategies to control the neovasculature development. Accomplishing this goal requires a thorough understanding of the mechanisms by which various signals affect the formation of blood vessels within biomaterials. A number of parameters affect vascular growth in porous scaffolds including: (i) porous architecture (pore size and porosity), (ii) transport of growth factors within the scaffolds (diffusion and concentration gradients), and (iii) cell response to growth factors (chemotaxis and chemokinesis) [78] . The following is an overview of the significant efforts that have been devoted to characterize and control the mechanisms that govern angiogenesis, as well as the major approaches to engineer vascularized biomaterials.
THE BIOLOGY OF ANGIOGENESIS
Blood vessel formation can be classified as angiogenesis or vasculogenesis, the former referring to formation of vessels from the pre-existing vasculature and the latter to the initial formation of vessels during embryonic development.
These processes are cumulatively referred to as neovascularization and involve complex interactions among a wide variety of regulatory factors and different cell types. Angiogenesis is a highly regulated and essential component of some physiological processes, such as wound healing, but if unregulated can lead or contribute to a variety of disease states. Due to its central role in tumor development, the various stages of angiogenesis have been studied most extensively in relation to cancer. A large number of studies have linked angiogenesis with tumor progression and a worsening of patient prognosis [79] [80] [81] . These studies have motivated the development and testing of a range of anti-angiogenic compounds in an effort to improve patient survival and quality of life for a range of tumor types. The importance of angiogenesis in tumor development was first recognized by the pioneering work of Judah Folkman in the 1970s. While initially controversial, examination of growth of tumors demonstrated the critical role that angiogenesis plays in the proliferation and dissemination of cancer cells. Once a small tumor mass becomes highly vascularized, nutrients normally delivered to healthy tissue will be consumed by dividing cancer cells and contribute to tumor growth. In such a case, cancer cells will displace healthy cells until the tumor reaches a diffusion-limited maximal size. While cancer cells will typically not initiate apoptosis in a low nutrient environment, they do require the basics of cell function like oxygen, glucose and amino acids.
Tumor cells will therefore continue dividing because they do so without regard to nutrient supply, but many will also perish because of insufficient nutrition. The tumor cells at the outer edge of a mass can readily access nutrients and therefore thrive, while internal cells die and create a necrotic tumor core. A steady state tumor size will emerge over time, which is a self-equilibration of cell growth and death given the current connection with the circulatory system. This diffusion-limited maximal size of most tumors is around 2 mm [82] . To grow beyond this size, the tumor must induce the formation of blood vessels to provide the nutrients necessary to fuel its continued expansion.
Whether triggered by a nutrient-starved tumor mass or an implanted tissue engineered scaffold, angiogenesis is a process proven to be the result of numerous interactions, among regulators, mediators and stimulatory molecules. These molecules regulate the proliferative and invasive activity of the endothelial cells that line blood vessels. Some of the most prominent angiogenesis stimulatory molecules include vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF), platelet-derived growth factor (PDGF) and certain matrix metalloproteinases (MMPs). Table 1 lists a number of stimulatory molecules and their role in angiogenesis. Some endogenous angiogenesis inhibitors are the interferon family ( , and ), thrombospondin-1 and -2, certain tissue inhibitors of matrix metalloproteinases and protein fragments such as angiostatin and endostatin.
The formation of a new vessel from the pre-existing vasculature is characterized by a number of sequential events. Prior to neovascularization, endothelial cells exist in a near quiescent state with only about 1 in every 10,000 (0.01%) undergoing division at a given time [83] . The turnover rate of endothelial cells increases up to 50-fold during the forma-tion of a new vascular sprout [84] . Endothelial cells can be classified as tip cells or stalk cells based on their location on the growing vascular sprout. These cell types are distinguished by a sharp contrast in notch activity. Formation of the vascular sprout requires the remodeling of the ECM surrounding the vessel from which this new branch emerges as well as disengagement of surrounding cells like pericytes. MMPs are responsible for degrading the ECM and as the endothelial cells proliferate and migrate along the gradient of angiostimulatory molecules, continued ECM turnover can release sequestered factors, which further accelerate this process. The tip and stalk cells provide the framework for the new vascular network [85, 86] . Endothelial cell sprouts organize into tubular structures and connect (anastomose) with each other as well as the existing vascular network.
Formation of new vessels during physiological angiogenesis is self-limited due to the production and release of angioinhibitory molecules ( Table 2 ). The equilibrium that normally exists between stimuli and inhibitors for angiogenesis is thought to be unbalanced during tumor cellinitiated neovascularization. While new vessels enable the tumor to grow by redefining the diffusion-limited maximal size, lack of vascularization curtails growth and favors tumor stabilization [82] . Some tumor masses never grow beyond this point, as they are incapable of recruiting new vessels. Acquisition of the angiostimulatory phenotype, also called the "angiogenic switch", is thought to result from a local imbalance between positive and negative regulators of angiogenesis. Efforts to drive angiogenesis in regenerative medicine strategies can use this process as a model with attention paid to encouraging the necessary remodeling and vascular maturation that are often absent in tumor vasculature.
STRATEGIES TO PROMOTE VASCULARIZATION OF BIOMATERIALS
Relying on infiltration of vessels into the scaffold after implantation has not been successful to date. Thus, off-theshelf tissue engineering products are limited to thin or avascular tissues (e.g. skin and cartilage) [87, 88] . Blood vessels from the surrounding host tissue initially invade a superficial distance in the constructs [89] [90] [91] . Importantly, vessel infiltration beyond this depth for larger scaffolds occurs too slowly to support newly formed tissue or cells seeded on these constructs [92] [93] [94] [95] . In addition, the newly formed capillaries formed are transient in nature [96] . Therefore, the development of approaches to enhance vascularization is essential for a successful clinical outcome of bone tissue engineering strategies. The tissue engineering community has designed different strategies to accelerate the infiltration of host vasculature and to encourage a greater depth of network formation into the scaffold (Fig. 1) . In the following, we review these approaches, their principles and drawbacks.
Angiogenic Growth Factor Delivery
Soluble growth factors regulate cell proliferation, migration, and cell-cell interactions during angiogenesis. Some of the known growth factors are VEGF, bFGF, PDFG and transforming growth factor-(TGF-). VEGF is considered as the most potent angiogenic growth factor that induces endothelial cell migration and proliferation [97] [98] [99] . Similar to VEGF, bFGF is synthesized by a number of cell types and is shown to stimulate endothelial cell proliferation and migration [100] . PDGF is shown to influence newly formed vessel maturation by recruiting pericytes [101, 102] . TGFis a multifunctional growth factor that is produced by variety of cell types such as fibroblasts and endothelial cells [103] .
Inspired by the mechanism of tumor angiogenesis, various groups have employed angiogenic growth factors to drive endothelial cells from host blood vessels to migrate into pore spaces of scaffolds. Through the use of growth factors such as VEGF, bFGF, and platelet-derived growth factor (PDGF alone or in combination new blood vessel formation can be accomplished [104] [105] [106] [107] [108] [109] [110] [111] [112] [113] . Growth factors encapsulated within a polymeric matrix or adsorbed to the surface of scaffolds have been demonstrated to establish a localized system capable of sustained protein delivery towards enhancement of vascular infiltration [114] [115] [116] [117] [118] . Direct growth factor delivery approaches however, face major drawbacks including the short half-life and toxicity of growth factors. In addition, the limited control over distribution of factors can lead to neovascularization at undesired sites, rheumatoid arthritis and tumor growth [119, 120] . 
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An alternative strategy to the delivery angiogenic growth factors within porous biomaterials is ex-vivo gene therapy. This strategy is based on the use of genetically modified cells to impart the natural release of bioactive proteins at physiological doses. Although gene therapy approaches have significant promise to improve biomaterial vascularization and ultimate fracture healing [121] [122] [123] [124] [125] , the host immune response to the viral vectors limits their application only to immune compromised animal models. Recent efforts by various groups on characterization of the biology of immune response to viruses and modification of the genome of vectors may help realize the full potential of gene therapy [126] [127] [128] [129] .
Cell Transplantation
Another strategy to promote vascular formation in biomaterials involves the incorporation of mature or progenitor endothelial cells and smooth muscle cells into scaffolds to serve as precursors of a vascular network. Endothelial cells form the lumen of blood vessels, constitute a barrier for nutrient transport and provide a non-thrombogenic surface for blood contact, playing a vital role in normal vascular function as well as angiogenesis [130] [131] [132] . Smooth muscle cells confer mechanical strength to the vessel directly and through production of ECM, and control vessel pressure and tone. The cell transplantation approach is based on the hypothesis that transplanted endothelial cells can anastomose with invading host cells and form a functional vascular network within the scaffolds. A clear advantage of this approach is the reduction of the time necessary for the formation of new blood vessels [133] [134] [135] [136] [137] [138] [139] [140] [141] .
The striking results of recent in vitro and in vivo endothelial cell transplantation studies have inspired the development and application of this strategy. Endothelial cells can organize into capillary-like structures containing lumen on collagen-based matrices [133, 134] . It was further demonstrated that these capillaries can integrate with the host vasculature and become functional perfused blood vessels [135] . As an example, Tremblay et al. demonstrated that the endothelial cells cultured in skin grafts can anastomose to the host vascular system within 4 days, whereas vascularization of a non-vascularized graft took as much as 14 days [142] . Remarkably, the injection of endothelial progenitor cells into acute ischemic sites was shown to result in neovascularization in a few weeks and augmented the surviving areas.
Mesenchymal stem cells (MSCs) have also been used in cell transplantation approaches to vascularize tissues. Under appropriate conditions, MSCs can differentiate along endothelial and smooth muscle cell lineage [51] [52] [53] [54] [55] [56] [57] [143] [144] [145] [146] [147] [148] [149] [150] . These cells can integrate with developing vasculature and new bone within the scaffolds, in a manner closely mimicking the normal development [151] [152] [153] [154] [155] [156] [157] . MSCs can also respond to microenvironmental changes and adjust their release profile accordingly. Once vascular cells have been recruited to the site, MSCs have the ability to integrate either into the forming vessels or the surrounding bone. This eliminates the need for clearance of the delivery vehicle as is seen with synthetic systems. Genetic modification of cells can increase the secretion rate of one or more agents but comes with the challenges and safety concerns associated with genetic engineering. Moreover, abnormal secretion of agents such as VEGF or bFGF could impede vascular maturation.
Cell-based strategies have a number of advantages, which include release of multiple factors controlled by environmental conditions, no requirement for large reservoirs of agents that could rupture prematurely and the ability of the delivery system to integrate with the developing tissue. A major challenge facing cell delivery strategies is the low viability of the transplanted cells. The limited anastomosis and integration of transplanted cells with host circulation jeopardizes successful results. In addition, endothelial cell transplantation approaches possess a limited control over blood vessel maturation in scaffolds.
Hypoxic-Conditioning to Drive Physiologic Release of Angiogenic Growth Factors
Cells used for tissue engineering are isolated from sites in the body where oxygen tensions are far below the 20% oxygen level used in cell culture studies. While cells in the lining of the lung and other highly perfused organs (such as the liver, heart and kidneys) exist in oxygen tensions similar to a 4-14% oxygen environment, many other cell types exist in the "hypoxic" range (less than 5%). Many of the in vitro studies in bone tissue engineering are conducted in oxygen environments, which do not accurately represent the in vivo conditions following implantation. A bone defect site requiring a scaffold to promote healing has a low oxygen tension (0-3% typically) due to damage to the local vasculature that accompanies bone loss [107, 158] . These conditions can have a negative impact on cell function but are also important in guiding cell phenotype. Low oxygen (hypoxic) signaling is critical in embryonic development and oxygen should be treated not only as a nutrient but also a potent signaling molecule [159] [160] [161] .
Angiogenesis in ischemic tissue is also a process driven by hypoxia and more specifically, hypoxia-inducible factors (HIFs). It has been estimated that 5% or more of our genes are regulated by HIF-1. VEGF, bFGF, angiopoietin 2 (Ang-2), TGF-and PDGF are examples of angiogenic molecules whose expression is increased by HIF-1 activity [162] [163] [164] . Hypoxia and HIF-1 are also implicated in the recruitment of circulating angiogenic cells, critical in vascular remodeling [165] [166] [167] . HIF-1-deficient mouse embryos fail to develop a vascular network and this genetic modification is embryonic lethal at midgestation.
Much of the prior research on the role of hypoxia and HIF-1 in driving vascular growth is in relation to cancer. As tumors expand past the limits of the local nutrient supply, angiogenic factors are secreted and additional vessels are recruited to the site fueling further expansion of the tumor. Interplay of multiple factors is essential for capillary development in-vivo and represents a strategy superior to those where a single agent is released to drive this process [168, 169] . VEGF has been a popular choice to drive vascular ingrowth into scaffolds but it does not work alone. VEGF can drive endothelial cell proliferation but it will also inhibit vascular maturation so at best its delivery needs to be closely regulated. Co-culture of endothelial and smooth muscles cells leads to reduced responsiveness to VEGF by the endothelial cells [170] . However, combinations of VEGF with other factors such as Ang-2 do stimulate capillary sprouting in co-culture systems. It is therefore not surprising that relying on controlled release of a single factor does not produce sufficient vascular development and responsive delivery of multiple agents is a more promising approach. Hypoxia (and specifically HIF-1) is shown to trigger secretion of a cocktail of angiogenic factors. This allows us to create an environment within the scaffold that more accurately mimics the one seen during physiological angiogenesis [171] . A schematic representation of this process is shown in Fig. (2) .
Microscale Technologies for Vascularization of Biomaterials
Studies have shown that it is challenging to create the natural complexity and spatial organization in engineered biomaterials especially when aiming to mimic highly vascularized tissues, such as, bone, liver or heart [172] . To address this constraint, microscale technologies, such as microfluidics, soft lithography, bioprinting and photolithography have been used to generate microvascular geometries in biomimetic constructs [58, [173] [174] [175] . Among these techniques, microfluidics is a widely used technique to generate vessel-like structures. Microfluidic channels with capillary patterns have been constructed utilizing hydrogel-based materials [176] [177] [178] . For example, 3D vascular tissues were mimicked by a microfluidic set-up, which enabled deposition of different types of vascular cells in each layer [173] . Additionally, perfusable channels were fabricated within cellencapsulated hydrogels to form microvasculatures in engineering biomaterials [177, 179] .
Soft lithography has been used to create vascular networks in biopolymers, such as bifurcating channels or capillaries, making use of elastomeric molds. For example, microvascular patterns from poly(glycerol sebacate) (PGS) were generated by creating the replica from silicon wafers [180] . The PGS scaffold was then assembled into a microfluidic system and cultured with endothelial cells under physiological flow conditions up to 14 days.
The formation of vascular structures can also be achieved by photolithoghrapic strategies based on modular assembly principles. In one study, sequential assembly of photopatterned microgels has been carried out to obtain cylindrical microvessels with single or branched lumens [58] . Another study has demonstrated the alignment of endothelial cells in hydrogel channels by means of photolithography for vascularization purposes [181] .
Researchers have recently introduced computer-aided rapid prototyping approaches to print vascularized tissues and organs for regenerative medicine [175] . These strategies have been used to develop microvascular networks in 3D hydrogels (Fig. 3) [175] . Single cells or cell aggregates are suspended in hydrogels droplets and then placed on predefined positions to generate the shape of the target tissue. In an attempt to create endothelial cell-loaded hydrogel tubes, computer-aided bioprinting strategies were utilized [182, 183] .
In addition to development of vascular microarchitectures in bioengineered constructs, formation of an endothelial monolayer inside the luminal region is critical for obtaining functional vessels [180] . For example, monolayers of 
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endothelial cells have been formed inside the lumen of a microvessel made of gelatin methacrylate (GelMA) hydrogel [184] . To accomplish this goal, self-assembled oligopeptide modified gold rods (600 um diameter) were seeded with endothelial cells and cultured until confluence was reached. Then hydrogel was deposited on the cells and exposed to ultra-violet (UV) light to induce crosslinking. An electrical potential was applied to remove the gold rods from cellhydogel assembly. Finally, media was perfused through the conduit with a syringe pump and cultured up to 15 days with no channel deformation.
To sum up, microscale technologies have been successfully utilized to induce or regulate in vitro vascularization of biomimetic materials for tissue engineering applications. Recapitulation of the native complexity and organization can potentially be improved using microscale technologies by controlling size, shape and geometry of vascular networks in engineered tissues.
Mechanical Mediation of Angiogenesis within Biomaterials
Angiogenesis is mediated by the endothelial cell microenvironment, with cues derived from soluble growth factors, insoluble ECM molecules, and membrane receptor signaling pathways [185] [186] [187] . While significant progress has been made in delineating how each of these factors individually modulates cell phenotype, signal integration and cell fate in a comprehensive microenvironment are only partially understood. Capillary growth involves many interactions among neighboring cells, which may be assumed to share a highly similar microenvironment in terms of soluble mitogen availability. To enable capillary formation, cell subsets within the same tissue region must simultaneously undergo differentiation, proliferation, migration, and apoptosis. Because neighboring cells will be exposed to a nearly identical cocktail of soluble factors, the local ECM, specifically its mechanical interaction with adhered cells, has been explored as a deterministic cue for variable cell behavior [186, 188, 189] . Fig. (3) . Bioprinting of cellular aggregates in hydrogel-based materials. Reproduced by permission of Science and Medicine [175] . 
3D ORGAN
In the course endothelial cell anchoring and exertion of contractile forces, deformations are induced in both the ECM and the cells. Cytoskeletal filaments, namely contractile microfilaments, mictotubules and intermediate filaments are implicated in the derivation and transmission of contractile forces as well as regulation of signaling pathways that result from cellular deformation [190] . The architecture and mechanical behavior of the cytoskeleton are typically described by a cellular tensegrity model [191] [192] [193] , although some critics still question the applicability of this idealization [194] . Tensegrity assumes that component arrangement and preloading result in all filaments existing in a state of continuous tension, and has successfully explained mechanical transduction in cells [191] . Physical distortions from the baseline conformation of the cytoskeletal network provide a molecular mechanism for signaling pathway regulation. It is now well-understood that cytoskeletal deformation causes biochemical changes in constituent filaments that in turn promote immobilization of a variety of soluble molecules. When immobilized on cytoskeletal filaments, the bioactivity of soluble molecules, which regulate DNA synthesis, RNA synthesis, protein synthesis and glycolosis are altered providing a link between mechanically induced deformations in the cytoskeleton and molecular pathways that impact angiogenesis [187, [195] [196] [197] [198] .
To explain the highly localized ECM regulation of cell behavior in angiogenesis, the microvascular tissue, which is typically considered a continuum with respect to mechanical properties, must display significant mechanical variance in adjacent regions that are on the order of cell size. Vascular ECM continuously remodels under conditions of health and disease, with remodeling processes causing local changes in tissue structure, composition, and mechanical properties [199, 200] . In angiogenesis, ECM remodeling has been observed to occur with the necessary spatial fidelity to account for variable interaction with neighboring cells, with reported differences in basement membrane thickness in regions comprising and adjacent to a growing capillary sprout [185, 201] . Assuming identical composition and structure, geometrical changes alone in the ECM would influence the mechanical behavior of adhered cells, specifically the induced deformation throughout the cytoskeletal network. Highly localized ECM remodeling and a resulting variability in ECM-cell interactions may account for the observed difference in neighboring cell behavior. Although the complex interplay among the microenvironmental regulators of angiogenesis is yet to be fully resolved, it is clear that mechanical signal transduction plays a critical role affecting cellular behavior that is required for vessel formation.
CONCLUDING REMARKS
The great interest in the tissue engineering community in directed angiogenesis has led to a variety of approaches that utilize cells, growth factors and materials to enhance vascular formation and infiltration in scaffolds. In pursuit of vascularization of biomaterials, the complexity of cellular and molecular principles that guide vascular development in tissues should be studied in depth. Current vascularization paradigms fail to mimic the native physiology and they solely rely on newly formed capillaries to grow in and form mature blood vessels. Capillary networks induced by these strategies are not connected to arteries within the scaffolds, thus, will regress within a short time.
In order to overcome the limitations of traditional strategies, new approaches must recapitulate the physiological pattern of morphological cues that guide vascular development. The emergence of microtechnologies, such as nano/microfabrication, drug delivery, and stem cell culture and manipulation have provided potential platforms to integrate concepts from vascular biology and engineering to apply design principles extracted from nature to the construction of vascularization strategies. In this context, thorough understanding of how molecular signals control physiology, how cells communicate with each other and their environment, and how molecular machines are coupled to force signal transduction is warranted. It is evident that simply copying the static blood vessel shape and apparent endothelial cell functions may not result in the best design. A deep understanding of the transient features of biological structures that reside within the static morphology is essential. To this end, new paradigms should be organized around the fundamental theme that vascularization strategies are only realizable when we allow the angiogenesis process within porous biomaterials to be guided under epigenetic cues.
